Malagueule's Lounge

[malagueule]

DD on Future growth and value creation of this stock - Big Money to be made here.

OWCP Looks to Bring Pharma-Grade Cannabis Therapeutics to Market!!!

OWCP is conducting clinical trials of cannabis-based treatments for multiple myeloma, psoriasis, fibromyalgia, post-traumatic stress disorder and migraines.

Multiple myeloma - orphan status designation

NEW YORK (GBI Research) - The global multiple myeloma treatment market value will expand from $7.3 billion in 2014 to $8.9 billion by 2021, representing a moderate Compound Annual Growth Rate (CAGR) of 4.6%, says business intelligence provider GBI Research.
link http://www.fiercepharma.com/marketing/global-multiple-myeloma-treatment-market-value-to-approach-9-billion-by-2021-says-gbi-0
-----
A form of bone marrow cancer that accounts for 2% of all cancer deaths. In preliminary studies, the Company demonstrated that some combinations of THC and CBD led to the eradication of 100% of myeloma cells in 60% of the cultured cells within 24 to 48 hours of exposure to the cannabinoid formulation. These early stage in-vitro results may be limited, but they demonstrate significant potential within the market.
Link http://www.baystreet.ca/viewarticle.aspx?id=437873

Psoriasis - marketing of a cannabinoid-based topical cream

The psoriasis market is set to rise from $6.6 billion in 2014 to over $13.3 billion by 2024 at a compound annual growth rate of 7.3%, according to research and consulting firm GlobalData.
link https://healthcare.globaldata.com/media-center/press-releases/pharmaceuticals/psoriasis-market-will-more-than-double-to-133-billion-by-2024-as-drugs-greatly-improve

fibromyalgia - orphan status designation

The treatment market value for fibromyalgia across the seven major markets (7MM) of the US, France, Germany, Italy, Spain, the UK, and Japan, will expand from $1.8 billion in 2013 at a tepid Compound Annual Growth Rate (CAGR) of 0.72% to reach $1.9 billion by 2023, according to research and consulting firm GlobalData
link https://healthcare.globaldata.com/media-center/press-releases/pharmaceuticals/fibromyalgia-treatment-market-value-will-crawl-to-19-billion-by-2023-says-globaldata

post-traumatic stress disorder ( PTSD )

The annual cost to society of anxiety disorders is estimated to be significantly over $42.3 billion, often due to misdiagnosis and under treatment. This includes psychiatric and non-psychiatric medical treatment costs, indirect workplace costs, mortality costs, and prescription drug costs. An estimated 8% of Americans - 24.4 million people - have PTSD at any given time. That is equal to the total population of Texas.
link http://www.ptsdunited.org/ptsd-statistics-2/

Technavio's analysts forecast the global PTSD therapeutics market to grow at a CAGR of 1.09% over the period 2014-2019.
link http://www.prnewswire.com/news-releases/global-post-traumatic-stress-disorder-therapeutics-market-2015-2019-300109175.html